Trials / Completed
CompletedNCT00048425
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levosimendan |
Timeline
- Start date
- 2002-09-01
- Completion
- 2004-12-01
- First posted
- 2002-11-04
- Last updated
- 2006-12-15
Locations
166 sites across 4 countries: United States, Australia, Canada, Israel
Source: ClinicalTrials.gov record NCT00048425. Inclusion in this directory is not an endorsement.